Vaxart (VXRT) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
20 Jul, 2026Opening remarks and agenda
Meeting called to order with introductions of board members, executive team, legal counsel, and independent auditor.
Agenda included voting on three proposals and a Q&A session for stockholders.
Board and executive committee updates
Board members and executive leadership introduced, including roles and responsibilities.
Inspector of Election appointed and sworn in to oversee voting process.
Shareholder proposals
Three proposals presented: election of directors, ratification of accounting firm, and advisory vote on executive compensation.
Voting conducted electronically and by proxy.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Vaxart
- Oral pill vaccine platform shows broad efficacy, strong safety, and major upcoming milestones.VXRT
Corporate presentation - Positive safety data, $27.2M revenue, $13.5M net loss, and cash runway into Q2 2027.VXRT
Q2 2026 - Contested director nominations resolved; Board to add new independent director and enhance governance.VXRT
Proxy filing - Proxy contest resolved, with focus on clinical milestones and strong governance ahead.VXRT
Proxy filing - Proxy contest resolved with board refreshment, new committees, and enhanced governance.VXRT
Proxy filing - Oral pill vaccine platform advances late-stage norovirus and COVID-19 trials with BARDA support.VXRT
H.C. Wainwright 27th Annual Global Investment Conference - BARDA contract boosts COVID-19 oral vaccine program, Q2 revenue up, but Nasdaq risk remains.VXRT
Q2 2024 - COVID-19 trial paused, norovirus phase I underway, revenue up, cash runway into Q4 2025.VXRT
Q4 2024 - Q1 revenue surged 857% to $20.9M as clinical trials advanced and net loss narrowed.VXRT
Q1 2025